LivaNova PLC (NASDAQ:LIVN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of LivaNova PLC (NASDAQ:LIVN) have been assigned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $83.50.

Several brokerages have issued reports on LIVN. Stifel Nicolaus set a $85.00 price objective on shares of LivaNova in a research report on Wednesday, August 5th. Zacks Research downgraded shares of LivaNova from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. KeyCorp upped their target price on shares of LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, June 22nd. Freedom Capital raised shares of LivaNova to a “hold” rating in a report on Tuesday, June 30th. Finally, Robert W. Baird dropped their price target on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $79.97 on Thursday. LivaNova has a 1-year low of $48.82 and a 1-year high of $85.76. The business has a 50-day moving average of $80.55 and a 200-day moving average of $72.20. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.45 and a quick ratio of 1.21. The company has a market capitalization of $4.41 billion, a price-to-earnings ratio of 23.66 and a beta of 0.86.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.17. The business had revenue of $390.59 million during the quarter, compared to analyst estimates of $380.50 million. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The company’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter last year, the firm earned $1.05 earnings per share. On average, equities analysts anticipate that LivaNova will post 3.77 EPS for the current fiscal year.

Institutional Trading of LivaNova

A number of hedge funds and other institutional investors have recently modified their holdings of the business. California State Teachers Retirement System increased its stake in shares of LivaNova by 7,996.3% in the second quarter. California State Teachers Retirement System now owns 5,154,505 shares of the company’s stock worth $423,855,000 after buying an additional 5,090,840 shares during the last quarter. Wellington Management Group LLP boosted its stake in LivaNova by 83.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after acquiring an additional 1,067,349 shares during the last quarter. Invesco Ltd. boosted its stake in LivaNova by 714.7% during the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock valued at $46,313,000 after acquiring an additional 902,447 shares during the last quarter. Scopia Capital Management LP acquired a new position in LivaNova during the 2nd quarter worth $36,657,000. Finally, Millennium Management LLC grew its holdings in LivaNova by 22.4% during the 3rd quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock worth $155,559,000 after acquiring an additional 544,033 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.